94 related articles for article (PubMed ID: 19071461)
1. Analysis and stability of polymorphs in tablets: The case of Risperidone.
Karabas I; Orkoula MG; Kontoyannis CG
Talanta; 2007 Feb; 71(3):1382-6. PubMed ID: 19071461
[TBL] [Abstract][Full Text] [Related]
2. Identification and quantitative determination of atorvastatin calcium polymorph in tablets using FT-Raman spectroscopy.
Skorda D; Kontoyannis CG
Talanta; 2008 Jan; 74(4):1066-70. PubMed ID: 18371751
[TBL] [Abstract][Full Text] [Related]
3. Quantitative determination of polymorphic impurity by X-ray powder diffractometry in an OROS formulation.
Varasteh M; Deng Z; Hwang H; Kim YJ; Wong GB
Int J Pharm; 2009 Jan; 366(1-2):74-81. PubMed ID: 18840515
[TBL] [Abstract][Full Text] [Related]
4. Non-destructive quantitative analysis of risperidone in film-coated tablets.
Orkoula MG; Kontoyannis CG
J Pharm Biomed Anal; 2008 Jul; 47(3):631-5. PubMed ID: 18359600
[TBL] [Abstract][Full Text] [Related]
5. Quantitative polymorph contaminant analysis in tablets using Raman and near infra-red spectroscopies.
Hennigan MC; Ryder AG
J Pharm Biomed Anal; 2013 Jan; 72():163-71. PubMed ID: 23146243
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the Sensitivity of Transmission Raman Spectroscopy for Polymorph Detection in Pharmaceutical Tablets.
Feng H; Bondi RW; Anderson CA; Drennen JK; Igne B
Appl Spectrosc; 2017 Aug; 71(8):1856-1867. PubMed ID: 28357920
[TBL] [Abstract][Full Text] [Related]
7. Characterization and monitoring of pseudo-polymorphs in manufacturing process by NIR.
Kamada K; Yoshimura S; Murata M; Murata H; Nagai H; Ushio H; Terada K
Int J Pharm; 2009 Feb; 368(1-2):103-8. PubMed ID: 19007870
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of drug physical form during granulation, tabletting and storage.
Williams AC; Cooper VB; Thomas L; Griffith LJ; Petts CR; Booth SW
Int J Pharm; 2004 May; 275(1-2):29-39. PubMed ID: 15081136
[TBL] [Abstract][Full Text] [Related]
9. Raman chemical mapping of low-content active pharmaceutical ingredient formulations. III. Statistically optimized sampling and detection of polymorphic forms in tablets on stability.
Šašić S; Mehrens S
Anal Chem; 2012 Jan; 84(2):1019-25. PubMed ID: 22191712
[TBL] [Abstract][Full Text] [Related]
10. Exploring the possible relationship between the drug release of Compritol®-containing tablets and its polymorph forms using micro X-ray diffraction.
Jannin V; Rosiaux Y; Doucet J
J Control Release; 2015 Jan; 197():158-64. PubMed ID: 25445699
[TBL] [Abstract][Full Text] [Related]
11. Drug characterization in low dosage pharmaceutical tablets using Raman microscopic mapping.
Henson MJ; Zhang L
Appl Spectrosc; 2006 Nov; 60(11):1247-55. PubMed ID: 17132441
[TBL] [Abstract][Full Text] [Related]
12. Lactose: a definitive guide to polymorph determination.
Kirk JH; Dann SE; Blatchford CG
Int J Pharm; 2007 Apr; 334(1-2):103-14. PubMed ID: 17110062
[TBL] [Abstract][Full Text] [Related]
13. Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation.
Rahman Z; Zidan AS; Khan MA
Int J Pharm; 2010 Nov; 400(1-2):49-58. PubMed ID: 20801200
[TBL] [Abstract][Full Text] [Related]
14. Influence of sample characteristics on quantification of carbamazepine hydrate formation by X-ray powder diffraction and Raman spectroscopy.
Tian F; Zhang F; Sandler N; Gordon KC; McGoverin CM; Strachan CJ; Saville DJ; Rades T
Eur J Pharm Biopharm; 2007 Jun; 66(3):466-74. PubMed ID: 17257816
[TBL] [Abstract][Full Text] [Related]
15. Quantitative determination of solid-state forms of a pharmaceutical development compound in drug substance and tablets.
Xie Y; Tao W; Morrison H; Chiu R; Jona J; Fang J; Cauchon N
Int J Pharm; 2008 Oct; 362(1-2):29-36. PubMed ID: 18588963
[TBL] [Abstract][Full Text] [Related]
16. Qualitative and quantitative analysis of clopidogrel bisulphate polymorphs.
Koradia V; Chawla G; Bansal AK
Acta Pharm; 2004 Sep; 54(3):193-204. PubMed ID: 15610616
[TBL] [Abstract][Full Text] [Related]
17. Measuring Bismuth Oxide Particle Size and Morphology in Film-Coated Tablets.
Fertaki S; Bagourakis G; Orkoula M; Kontoyannis C
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458800
[TBL] [Abstract][Full Text] [Related]
18. Process induced transformations during tablet manufacturing: phase transition analysis of caffeine using DSC and low frequency micro-Raman spectroscopy.
Hubert S; Briancon S; Hedoux A; Guinet Y; Paccou L; Fessi H; Puel F
Int J Pharm; 2011 Nov; 420(1):76-83. PubMed ID: 21884769
[TBL] [Abstract][Full Text] [Related]
19. Non-destructive determination of the coating film thickness by X-ray powder diffractometry and correlation with the dissolution behavior of film-coated tablets.
Yamada H; Terada K; Suryanarayanan R
J Pharm Biomed Anal; 2010 Mar; 51(4):952-7. PubMed ID: 19945243
[TBL] [Abstract][Full Text] [Related]
20. Quantification of crystalline forms in active pharmaceutical ingredient and tablets by X-ray powder diffraction.
Cooper VB; Pearce GE; Petts CR
J Pharm Pharmacol; 2003 Sep; 55(9):1323-9. PubMed ID: 14604477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
